US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Research & Development Market Research Reports & Industry Analysis

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

RSS Feeds

Research & Development Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market
11/20/2014 | published by: Frost & Sullivan
... in addition to standard of care. It does not evaluate the market for corticosteroids, non-steroidal anti-inflammatory agents (NSAIDs), and other analgesics or background disease-modifying antirheumatic drug (DMARD) therapy. The study takes into account products in ...  |  read more...
USD 4,000
Global Analysis of Ebola Disease
11/18/2014 | published by: Frost & Sullivan
... of rapid tests and quality treatment. The porous borders of Western Africa and its neighboring countries still pose the threat of a global Ebola epidemic. China and India pose the most risk because of their ...  |  read more...
USD 3,500
Global Life Sciences BPO Market 2014-2018
11/12/2014 | published by: TechNavio - Infiniti Research Ltd.
... stringent regulatory environment and the patent expiry of several important drugs are leading to diminishing profit margins to many life science companies. This scenario has forced life science companies to outsource their R&D activities and ...  |  read more...
USD 2,500
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
11/10/2014 | published by: Frost & Sullivan
... States MS market is entering a new phase of growth that is driven by the development of innovative therapeutic platforms. Recent therapeutics advances focus on a couple of factors: Improving tolerability of existing products specifically ...  |  read more...
USD 4,000
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... 395 Alpha6Beta4 integrin pathway targeting drugs in 1391 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 177 drugs. ...  |  read more...
USD 6,746
Apoptosis in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... cancer cells. There are today 346 companies plus partners developing 440 apoptotic drugs in 2110 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the ...  |  read more...
USD 6,746
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 213 companies plus ...  |  read more...
USD 6,746
Biologicals in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... developing 1784 biological drugs in 4104 developmental projects in cancer. In addition, there are 28 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 950 drugs. Biologicals In ...  |  read more...
USD 11,246
Bladder Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... treated early, the 5 year survival rate is 94%. There are today 101 companies plus partners developing 129 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ...  |  read more...
USD 4,496
Brain Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
USD 6,746
Cancer Stem Cells Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ...  |  read more...
USD 6,746
Cellular Therapy in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... the accumulated number of ceased drugs over the last years amount to another 65 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ...  |  read more...
USD 4,496
Colorectal Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 316 companies ...  |  read more...
USD 6,746
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ...  |  read more...
USD 6,746
Head and Neck Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 51 drugs. Head And Neck Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 6,746
Hematological Cancers Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... 796 hematological cancer drugs in 1797 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 243 drugs. Hematological Cancers ...  |  read more...
USD 8,996
ID Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 94 companies plus partners developing 96 ID pathway targeting drugs in ...  |  read more...
USD 2,246
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 86 companies plus partners developing 86 IL-1 pathway targeting drugs in 332 developmental projects in cancer. In ...  |  read more...
USD 4,496
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 27 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 2,246
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 4,496
Immunotherapy in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 595 companies plus partners developing 1158 cancer immunotherapy drugs in 3012 developmental projects in cancer. In addition, there are 19 ...  |  read more...
USD 11,025
Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... partners developing 397 Leptin pathway targeting drugs in 1483 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 193 ...  |  read more...
USD 6,746
Lymphoma Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 116 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you ...  |  read more...
USD 6,746
Neuroendocrine Tumors Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 18 drugs. Neuroendocrine Tumors Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are ...  |  read more...
USD 4,496
Notch Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... are today 252 companies plus partners developing 348 Notch pathway targeting drugs in 1309 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
USD 6,746
< prev 1    3  4  5  6  7  8  9  10